Potential strategies for increasing drug-discovery productivity

Future Medicinal Chemistry

Volumn 6, Issue 5, 2014, Pages 515-527

  Cumming, John G ^a   Finlay, M Raymond V ^a   Giordanetto, Fabrizio ^b   Hemmerling, Martin ^b   Lister, Troy ^a   Sanganee, Hitesh ^a   Waring, Michael J ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; BEDAQUILINE; BOCEPREVIR; CABOZANTINIB; CRIZOTINIB; CROFELEMER; GEFITINIB; HOMOHARRINGTONINE; ICATIBANT; IMATINIB; INGENOL MEBUTATE; IVACAFTOR; LINACLOTIDE; LOMITAPIDE; LORCASERIN; MARAVIROC; MIRABEGRON; PERAMPANEL; PLERIXAFOR; RETIGABINE; ROFLUMILAST; RUXOLITINIB; TERIFLUNOMIDE; VEMURAFENIB; VISMODEGIB;

BINDING KINETICS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SCREENING; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; PHENOTYPE; POLYPHARMACOLOGY; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SIMULATION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; ENZYMES; HUMANS; PHARMACOKINETICS; PHENOTYPE; POLYPHARMACOLOGY; RECEPTORS, CELL SURFACE; SMALL MOLECULE LIBRARIES;

EID: 84896947917     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.7     Document Type: Review

References (87)

1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R and D efficiency. Nat. Rev. Drug Discov. 11(3), 191-200 (2012).
2. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov. Today 17(19-20), 1088-1102 (2012).
3. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R and D. Nat. Rev. Drug Discov. 10(6), 428-438 (2011).
4. Ruffolo RR. Why has R and D productivity declined in the pharmaceutical industry? Expert Opin. Drug Discov. 1(2), 99-102 (2006).
5. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R and D productivity: the pharmaceutical industrys grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010). n Gives an economic model of R and D productivity based on comprehensive, industry-wide data.
6. Morgan P, Van Der Graaf PH, Arrowsmith J et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17(9-10), 419-424 (2012).
7. Ullman F, Boutellier R. A case study of lean drug discovery: from project driven research to innovation studios and process factories. Drug Discov. Today 13(11-12), 543-550 (2008).
8. Andersson S, Armstrong A, Bjore A et al. Making medicinal chemistry more effective - application of Lean Sigma to improve processes, speed and quality. Drug Discov. Today 14(11-12), 598-604 (2009).
9. Plowright AT, Johnstone C, Kihlberg J, Pettersson J, Robb G, Thompson RA. Hypothesis driven drug design: improving quality and effectiveness of the design-make- test-analyze cycle. Drug Discov. Today 17(1-2), 56-62 (2012).
10. Elebring T, Gill A, Plowright AT. What is the most important approach in current drug discovery: doing the right things or doing things right? Drug Discov. Today 17(21-22), 1166-1169 (2012).
11. Johnstone C, Pairaudeau G, Pettersson JA. Creativity, innovation and lean sigma: a controversial combination? Drug Discov. Today 16(1-2), 50-57 (2011).
12. Cumming JG, Davis AM, Muresan S, Haeberlein M, Chen H. Chemical predictive modeling to improve compound quality. Nat. Rev. Drug Discov. 12(12), 948-962 (2013).
13. Leahy DE. Drug discovery information integration: virtual humans for pharmacokinetics. Drug Discov. Today 2(2), 78-84 (2004).
14. Johnstone C. Medicinal chemistry matters - a call for discipline in our discipline. Drug Discov. Today 17(11-12), 538-543 (2012).
15. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov. Today 10(2), 139-147 (2005).
16. Sams-Dodd F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov. Today 18(5-6), 211-217 (2013).
17. Lindsay MA. Finding new drug targets in the 21st century. Drug Discov. Today 10(23-24), 1683-1687 (2005).
18. Sams-Dodd F. Drug discovery: selecting the optimal approach. Drug Discov. Today 11(9-10), 465-472 (2006).
19. Swinney DC, Anthony J. How were new medicines discovered? Nat. Rev. Drug Discov. 10(7), 507-519 (2011).
20. Brown D. Unfinished business: target-based drug discovery. Drug Discov. Today 12(23-24), 1007-1012 (2007).
21. Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov. Today 11(7-8), 355-363 (2006).
22. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55(10), 4527-4538 (2012).
23. Lee JC, Laydon JT, McDonnell PC et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372(6508), 739-746 (1994).
24. Hart CP. Finding the target after screening the phenotype. Drug Discov. Today 10(7), 513-519 (2005).
25. Schenone M, Dancik V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9(4), 232-240 (2013).
26. Ziegler S, Pries V, Hedberg C, Waldmann H. Target identification for small bioactive molecules: finding the needle in the haystack. Angew. Chem. Int. Ed. 52(10), 2744-2792 (2013).
27. Chung CW, Coste H, White JH et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54(11), 3827-3838 (2011).
28. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol. Biosyst. 5(9), 1051-1057 (2009).
29. Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today 18(9-10), 495-501 (2013).
30. Viayna E, Sola I, Di Pietro O, Munoz-Torrero D. Human disease and drug pharmacology, complex as real life. Curr. Med. Chem. 20(13), 1623-1634 (2013).
31. Frantz S. Drug discovery: playing dirty. Nature 437(7061), 942-943 (2005).
32. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat. Biotechnol. 24(7), 805-815 (2006).
33. Hopkins AL. Network pharmacology. Nat. Biotechnol. 25(10), 1110-1111 (2007).
34. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4(11), 682-690 (2008).
35. Metz JT, Hajduk PJ. Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. Curr. Opin. Chem. Biol. 14(4), 498-504 (2010).
36. Sirota M, Dudley JT, Kim J et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3(96), 96ra77 (2011).
37. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat. Biotechnol. 25(10), 1119-1126 (2007).
38. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel. 13(3), 297-309 (2010).
39. Xie L, Xie L, Kinnings SL, Bourne PE. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu. Rev. Pharmacol. Toxicol. 52, 361-379 (2012).
40. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16(1), 127-136 (2006).
41. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21), 6523-6543 (2005).
42. Morphy R, Rankovic Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des. 15(6), 587-600 (2009).
43. Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem. 49(16), 4961-4970 (2006).
44. Steinfeld T, Hughes AD, Klein U, Smith JA, Mammen M. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol. Pharmacol. 79(3), 389-399 (2011).
45. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 53(4), 1413-1437 (2010).
46. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5(10), 835-844 (2006).
47. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des. Devel. Ther. 5, 471-485 (2011).
48. Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 462(7270), 175-181 (2009).
49. Achenbach J, Tiikkainen P, Franke L, Proschak E. Computational tools for polypharmacology and repurposing. Future Med. Chem. 3(8), 961-968 (2011).
50. Swinney DC. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr. Top. Med. Chem. 6(5), 461-478 (2006).
51. Fuchs B, Breithaupt-Grogler K, Belz GG et al. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J. Pharm. Pharmacol. 52(9), 1075-1083 (2000).
52. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5(9), 730-739 (2006).
53. Lu H, Tonge PJ. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14(4), 467-474 (2010).
54. Yin N, Pei J, Lai L. A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels. Mol. BioSyst. 9, 1381-1389 (2013).
55. Miller DC, Lunn G, Jones P, Sabnis Y, Davies NL, Driscoll P. Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target. Med. Chem. Commun. 3, 449-452 (2012).
56. Jin M, Petronella BA, Cooke A et al. Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics. ACS Med. Chem. Lett. 4(7), 627-631 (2013).
57. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307-317 (2011).
58. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102(21), 7665-7670 (2005).
59. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343(2), 342-350 (2012).
60. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M. Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol. Sci. 29(6), 280-286 (2008).
61. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67(4), 1268-1282 (2005).
62. Napier C, Sale H, Mosley M et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem. Pharmacol. 71(1-2), 163-172 (2005).
63. Price S. Putative allosteric MEK1 and MEK2 inhibitors. Expert Opin. Ther. Pat. 18(6), 603-627 (2008).
64. Hatzivassiliou G, Haling JR, Chen H et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAFdriven cancers. Nature doi:10.1038/ nature12441 (2013) (Epub ahead of print).
65. Trinquet E, Bouhelal R, Dietz M. Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay. Expert Opin. Drug Discov. 6(10), 981-994 (2011).
66. Scott CW, Peters MF. Label-free whole-cell assays: expanding the scope of GPCR screening. Drug Discov. Today 15(17-18), 704-716 (2010).
67. Wootten D, Christopoulos A, Sexton PM. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. 12(8), 630-644 (2013).
68. Seydel JK, Schaper KJ, Coats EA et al. Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines. J. Med. Chem. 37(19), 3016-3022 (1994).
69. Fischer H, Machen TE, Widdicombe JH et al. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J. Ethnopharmacol. 93(2), 351-357 (2004).
70. Andries K, Verhasselt P, Guillemont J et al. A Diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223-227 (2005).
71. Marin D, Kaeda JS, Andreasson C et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103(9), 1850-1855 (2005).
72. Patterson JW, Cheung PS, Ernest MJ. 3-carboxy-5-methyl-N-4- (trifluoromethyl)phenyl]-4- isoxazolecarboxamide, new prodrug for the antiarthritic agent 2-cyano-3-hydroxy-N-4- (trifluoromethyl)phenyl]-2- butenamide. J. Med. Chem. 35, 507-510 (1992).
73. Hampson P, Chahal H, Khanim F et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 106(4), 1362-1368 (2005).
74. Hock FJ, Wirth K, Albus U et al. Hoe 140 a new potent and long acting bradykininantagonist: in vitro studies. Br. J. Pharmacol. 102(3), 769-773 (1991).
75. Bollag G, Tsai J, Zhang J et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11, 873-886 (2012).
76. Venkatraman S, Bogen SL, Arasappan A et al. Discovery of (1R,5S)-N-3-amino-1- (cyclobutylmethyl)-2,3-dioxopropyl]- 3-2(S)-(1,1- dimethylethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo3.1.0]hexan-2(S)- carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 49(20), 6074-6086 (2006).
77. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017.alpha.-hydroxylase- C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463-2471 (1995).
78. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297(1), 267-279 (2001).
79. Robl JA, Sulsky R, Sun C et al. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem. 44(6), 851-856 (2001).
80. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer. Ther. 10(12), 2298-2308 (2011).
81. Hibi S, Ueno K, Nagato S et al. Discovery of 2-(2-oxo-1-phenyl-5-pyridin- 2-yl-1,2- dihydropyridin-3-yl)benzonitrile (Perampanel): a novel, noncompetitive a-amino-3-hydroxy-5-methyl-4- isoxazolepropanoic acid (AMPA) receptor Antagonist. J. Med. Chem. 55, 10584-10600 (2012).
82. Busby RW, Bryant AP, Bartolini WP et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649(1), 328-335 (2010).
83. Maruyama T, Onda K, Hayakawa M et al. Synthesis and evaluation of novel phenylethanolamine derivatives containing acetanilides as potent and selective beta3- adrenergic receptor agonists. Chem. Pharm. Bull. (Tokyo) 58(4), 533-545 (2010).
84. Smith BM, Smith JM, Tsai JH et al. Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 15(5), 1467-1470 (2005).
85. Van Goor F, Hadida S, Grootenhuis PDJ et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106(44), 18825-18830 (2009).
86. Castanedo GM, Wang S, Robarge KD et al. Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway. Bioorg. Med. Chem. Lett. 20, 6748-6753 (2010).
87. Quintás-Cardama A, Vaddi K, Liu P et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109-3117 (2010).